The Triple-Negative Breast Cancer Treatment (TNBC) market is expected to grow at an alarming rate since breast cancer is the second leading cause of deaths in women out of which 20% of the cases are TNBC. The rising awareness of cancer treatment therapies and a robust pipeline of drugs will propel the growth of this market. Increased research and development of innovative treatment therapies and drugs for accurate diagnosis of the tumour during its early stages and successful treatment will spur this market. The TNBC market is unaffected by the COVID -19 wave harassing the global population since this is a treatment targeted on a specific group of patients. The main challenge faced by the market will be high treatment costs and associated insurance issues. The regulations put forth by the government for drug approvals can hamper the growth of the triple-negative breast cancer treatment market.
The entire triple-negative breast cancer treatment market has been sub-categorized into drug type and distribution channel. current and future demand for triple-negative breast cancer treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
The major players in the triple-negative breast cancer treatment market include AstraZeneca PLC, Johnson & Johnson Services, Inc., Pfizer, Inc., F. Hoffman – La Roche Ltd., Bristol-Myers Squibb Company, Novartis AG, Mylan N.V., Eli Lilly and Company, Celgene Corporation, Sanofi S.A., Others.
By Drug Type
- Doxorubicin
- Cyclophosphamide
- Paclitaxel
- Docetaxel
- Carboplatin/Cisplatin
- Others
By Distribution Channel
- Hospital Pharmacies
- Specialty Cancer Clinics
Source: https://www.valuemarketresearch.com/report/triple-negative-breast-cancer-treatment-market
Naira Shekhawat has been into Content Writing just after completing her Graduation in English Literature. Her love for words has won her many accolades in her respective jobs ever since. Naira covers business sections for VMR News. She is a traveller by heart and loves writing on food blogs as a freelancer.